AJCC Cancer Staging Manual, 6th edition

A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer

Background The aim was to study the clinical utility of AJCC 8th edition prognostic stage system for patients with breast cancer. Methods According to the AJCC 8th edition cancer staging system, a total of 784 patients with breast cancer diagnosed by Department of Breast Surgery in Peking University Shenzhen Hospital from January 2011 to June 2016 were analyzed in anatomic and prognostic stag...

Lymphnode staging update in the American Joint Committee on Cancer 8th Edition cancer staging manual.

Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems

Intrahepatic cholangiocarcinoma (ICC) was differentiated from hepatocellular carcinoma, as defined in the American Joint Committee on Cancer (AJCC) 6th edition staging manual, using the revised staging system described in the AJCC 7th edition staging manual. This study was conducted to analyze the application of the AJCC 6th and 7th edition staging classifications and to evaluate a modified sta...

The New Edition (7) AJCC Staging System for Breast Cancer A Summary of Key Changes

Introduction: On January 1, 2010, the new 7 edition of the AJCC staging system for breast cancer went into effect. The changes reflect advances in both management options and in prognostic information; they also reflect clarifications in definitions used in the 6 edition. Nevertheless, there are still issues in the new system that require careful reading to understand and there are some that re...

Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Answer questions and earn CME/CNE The eighth edition of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) Staging Manual has been updated and improved to ensure the highest degree of clinical relevance and to improve its utility for patient evaluation and clinical research. Major changes include: 1) pathologically organ-confined disease is now considered pT2 and is no lo...